These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7940955)

  • 1. Computerized quantitation of immunosuppressive synergy for clinical protocol design.
    Chou TC; Stepkowski SM; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):3043-5. PubMed ID: 7940955
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic effect of 3M KCl-extracted donor antigens with cyclosporine or cyclosporine/rapamycin to prolong heart allograft survival in rats.
    Hamashima T; Stepkowski SM; Smith S; Kahan BD
    Transplant Proc; 1994 Oct; 26(5):3053-5. PubMed ID: 7940960
    [No Abstract]   [Full Text] [Related]  

  • 3. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A.
    Hoshino Y; Suzuki C; Ohtsuki M; Masubuchi Y; Amano Y; Chiba K
    Transplant Proc; 1996 Apr; 28(2):1060-1. PubMed ID: 8623226
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolongation of cardiac allograft survival in rats following combination treatment with 2-chloro-2'-deoxyadenosine and cyclosporine: a novel immunosuppressive strategy.
    Nawrocki G; Grieb P; Górski A; Danielewicz R; Rowiński W
    Transplant Proc; 1996 Dec; 28(6):3538-9. PubMed ID: 8962374
    [No Abstract]   [Full Text] [Related]  

  • 5. Synergistic activity of the triple combination: cyclosporine, rapamycin, and brequinar.
    Stepkowski SM; Kahan BD
    Transplant Proc; 1993 Jun; 25(3 Suppl 2):29-31. PubMed ID: 8516939
    [No Abstract]   [Full Text] [Related]  

  • 6. Correlation of the in vitro and in vivo immunosuppressive activity of brequinar sodium.
    Eiras-Hreha G; Cramer DV; Cajulis E; Cosenza C; Mills L; Hough K; Frankland M; Chapman F; Wang H; Zajac I
    Transplant Proc; 1993 Feb; 25(1 Pt 1):708-9. PubMed ID: 8438448
    [No Abstract]   [Full Text] [Related]  

  • 7. Xanthines: ideal immunosuppressants for combination with cyclosporine?
    Lin Y; Segers C; Mikhalsky D; Schönharting M; Waer M
    Transplant Proc; 1996 Dec; 28(6):3102. PubMed ID: 8962202
    [No Abstract]   [Full Text] [Related]  

  • 8. Progressive change in tolerance mechanisms after withdrawing combination immunosuppression with cyclosporine and rapamycine or leflunomide.
    Lin Y; Waer M
    Transplant Proc; 1996 Dec; 28(6):3159. PubMed ID: 8962224
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunosuppressants suppressing signal 2 of T-cell activation enable CsA to induce operational transplantation tolerance in a strongly immunogenic heart allograft model in rats.
    Lin Y; Goebels J; Vandeputte M; Waer M
    Transplant Proc; 1996 Apr; 28(2):977-8. PubMed ID: 8623485
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunosuppressive effects of leflunomide in a cardiac allograft model.
    Williams JW; Xiao F; Foster PF; Chong A; Sharma S; Bartlett R; Sankary HN
    Transplant Proc; 1993 Feb; 25(1 Pt 1):745-6. PubMed ID: 8438465
    [No Abstract]   [Full Text] [Related]  

  • 11. Early experience with cyclosporine: a historic perspective.
    Kostakis A
    Transplant Proc; 2004 Mar; 36(2 Suppl):22S-24S. PubMed ID: 15041302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the use of brequinar sodium and cyclosporine combination therapy for preventing rat cardiac allograft rejection.
    Cosenza CA; Cramer DV; Eiras-Hreha G; Cajulis E; Wang HK; Makowka L
    Transplant Proc; 1993 Jun; 25(3 Suppl 2):57-8. PubMed ID: 8516945
    [No Abstract]   [Full Text] [Related]  

  • 13. Control and reversal of chronic xenograft rejection in hamster-to-rat cardiac transplantation.
    Xiao F; Shen J; Chong A; Liu W; Foster P; Blinder HL; Sankary H; McChesney L; Mital D; Williams JW
    Transplant Proc; 1996 Apr; 28(2):691-2. PubMed ID: 8623348
    [No Abstract]   [Full Text] [Related]  

  • 14. CsA therapy affects the direct and indirect antigen-presentation pathway in cardiac allograft recipients.
    van Besouw NM; Vaessen LM; Balk AH; Mochtar B; Claas FH; Weimar W
    Transplant Proc; 1996 Dec; 28(6):3135-6. PubMed ID: 8962214
    [No Abstract]   [Full Text] [Related]  

  • 15. Route of administration determines the efficacy of rapamycin but not the mechanisms of tolerance induced by it in rats.
    Lin Y; Rutgeerts O; Waer M
    Transplant Proc; 1996 Dec; 28(6):3057. PubMed ID: 8962185
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunosuppression with the vitamin D analogue MC 1288 in experimental transplantation.
    Johnsson C; Binderup L; Tufveson G
    Transplant Proc; 1996 Apr; 28(2):888-91. PubMed ID: 8623448
    [No Abstract]   [Full Text] [Related]  

  • 17. Additive immunosuppressive effect of hydroxycamptothecin and cyclosporine on rejection of heart transplantation in rats.
    Shi B; Cai M; Qian Y; Zhou W; Mo C; Wang Y
    Transplant Proc; 2007 Dec; 39(10):3429-31. PubMed ID: 18089398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of leflunomide and cyclosporine on aortic allograft chronic rejection in the rat.
    MacDonald AS; Sabr K; MacAuley MA; McAlister VC; Bitter-Suermann H; Lee T
    Transplant Proc; 1994 Dec; 26(6):3244-5. PubMed ID: 7998130
    [No Abstract]   [Full Text] [Related]  

  • 19. Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative.
    Schorlemmer HU; Seiler FR; Bartlett RR
    Transplant Proc; 1993 Feb; 25(1 Pt 1):763-7. PubMed ID: 8438472
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term graft acceptance in allografted rats and dogs by treatment with a novel immunosuppressant, FTY720.
    Suzuki S; Enosawa S; Kakefuda T; Amemiya H; Hoshino Y; Chiba K
    Transplant Proc; 1996 Jun; 28(3):1375-6. PubMed ID: 8658701
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.